ecancer
ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.
ESMO 2022 on the Phase 3 RATIONALE-301 Study: Tislelizumab OS Benefit vs. Sorafenib as 1L Treatment for Unresectable HCC
By
ecancer
FEATURING
Richard S. Finn
By
ecancer
FEATURING
Richard S. Finn
Comments 0
Login to view comments.
Click here to Login
